BioCentury | Jul 13, 2015
Finance

Mid-cap hot streak

Almost all of the biotech market cap tiers tracked by BioCentury ended the second quarter in the black. The lone exception was companies valued below $200 million, which collectively fell a median 1.2%. Big cap...
BC Week In Review | Jun 1, 2015
Clinical News

Xifaxan rifaximin regulatory update

FDA approved an sNDA for Xifaxan rifaximin 550 mg tablets from Valeant to treat irritable bowel syndrome with diarrhea (IBS-D) in adults. Valeant said the non-aminoglycoside, semi-synthetic antibiotic derived from rifamycin SV is the first...
BC Extra | May 28, 2015
Company News

FDA approves pair of IBS therapies

FDA approved Viberzi eluxadoline ( JNJ-270189066 ) from Actavis plc (NYSE:ACT) and Xifaxan rifaximin from Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) to treat irritable bowel syndrome with diarrhea (IBS-D) in adults. Actavis obtained Viberzi, a locally acting...
BioCentury | Apr 6, 2015
Finance

Q is for quiet

Investors expect 2Q15 to be fairly quiet in terms of news flow until the deluge of data for cancer immunotherapy combinations come out in June at the American Society of Clinical Oncology meeting. The problem...
BC Week In Review | Mar 30, 2015
Company News

Alfa Wassermann, Norgine sales and marketing update

The U.K.’s NICE issued final guidance recommending 550 mg Targaxan rifaximin from Norgine to prevent recurrence of episodes of overt hepatic encephalopathy (HE) in adults -- its approved indication in the EU. The guidance is...
BC Week In Review | Mar 16, 2015
Company News

Salix, Endo deal

Endo submitted a proposal to acquire Salix for $175 per share in cash and stock, or about $11.2 billion. The price, an 11% premium to Salix’s close of $157.65 on March 10, the day before...
BC Extra | Mar 12, 2015
Top Story

Endo the road for Salix

Salix Pharmaceuticals Ltd. (NASDAQ:SLXP) gained $10.96 to $168.61 after Endo International plc (NASDAQ:ENDP; TSX:ENL) attempted to outbid Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) with a buyout offer for Salix of $175 per share, or $11.2...
BC Week In Review | Mar 2, 2015
Company News

Salix Pharmaceuticals Ltd, Valeant Pharmaceuticals deal

Valeant will acquire Salix for $158 per share in cash, or about $14.5 billion. The price is $0.15 above Salix’s share price on Feb. 20, before the deal was announced, and a 3.7% premium to...
BC Extra | Feb 24, 2015
Company News

Valeant to acquire Salix for $14.5B

Valeant Pharmaceuticals International Inc. (TSX:RVX; NYSE:VRX) will acquire Salix Pharmaceuticals Ltd. (NASDAQ:SLXP) for $158 per share, or $14.5 billion in cash. Salix markets a portfolio of gastrointestinal drugs including Xifaxan rifaximin , which accounted for $414.3...
BC Week In Review | Feb 23, 2015
Clinical News

Targaxan rifaximin regulatory update

The U.K.’s NICE issued a final appraisal determination (FAD) recommending 550 mg Targaxan rifaximin from Norgine to prevent recurrence of episodes of overt hepatic encephalopathy (HE) in adults -- its approved indication in the EU....
Items per page:
1 - 10 of 231